You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

rHuPH20

Showing 1 - 25 of 119
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Plasma Cell Myeloma Trial in Philadelphia (Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life

Not yet recruiting
  • Plasma Cell Myeloma
  • Daratumumab and Hyaluronidase-fihj
  • +3 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Aug 19, 2022

Plasma Cell Myeloma Trial (Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone)

Not yet recruiting
  • Plasma Cell Myeloma
  • (no location specified)
Dec 22, 2022

Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8 Trial in Los Angeles (Atezolizumab

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +10 more
  • Atezolizumab and Recombinant Human Hyaluronidase
  • Survey Administration
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Jan 31, 2023

HIV Trial in Austin (VH3810109, rHuPH20)

Recruiting
  • HIV Infections
  • VH3810109
  • rHuPH20
  • Austin, Texas
    GSK Investigational Site
Sep 19, 2022

Healthy Trial in London (Ravulizumab, rHuPH20)

Completed
  • Healthy
  • London, United Kingdom
    Clinical Trial Site
May 25, 2022

AL Amyloidosis Trial (procedure, drug, other)

Not yet recruiting
  • AL Amyloidosis
  • Autologous Hematopoietic Stem Cell Transplantation
  • +15 more
  • (no location specified)
Aug 28, 2023

HIV Trial in Las Vegas (Cabotegravir 200 mg/mL, Cabotegravir 400 mg/mL, Recombinant human hyaluronidase PH20 (rHuPH20))

Recruiting
  • HIV Infections
  • Cabotegravir 200 mg/mL
  • +2 more
  • Orlando, Florida
  • +3 more
Dec 1, 2022

Primary Immunodeficiency Diseases (PID) Trial (TAK-881, HYQVIA)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • TAK-881
  • HYQVIA
  • (no location specified)
Feb 23, 2023

Multiple Myeloma Trial in Worldwide (Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC

Active, not recruiting
  • Multiple Myeloma
  • Daratumumab Subcutaneous (SC) Administration
  • Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
  • Atlanta, Georgia
  • +11 more
Aug 11, 2022

Healthy Trial in London (ALXN1720 SC, ALXN1720 IV, rHuPH20)

Completed
  • Healthy
  • ALXN1720 SC
  • +4 more
  • London, United Kingdom
    Clinical Study Site
Feb 2, 2022

Primary Immunodeficiency Diseases (PID) Trial (TAK-881)

Not yet recruiting
  • Primary Immunodeficiency Diseases (PID)
  • TAK-881
  • (no location specified)
Oct 4, 2023

Healthy Volunteers Trial in Groningen (ARGX-117, Placebo, ARGX-117 + rHuPH20)

Active, not recruiting
  • Healthy Volunteers
  • ARGX-117
  • +5 more
  • Groningen, Netherlands
    Investigator Site 1
Feb 7, 2022

Dermatitis, Allergic Contact Trial in Michigan City (rHuPH20, Placebo)

Completed
Has Results
  • Dermatitis, Allergic Contact
  • rHuPH20
  • Placebo
  • Michigan City, Indiana
    Symbio Phase I Unit, Saint Anthony Memorial Research Center
Nov 19, 2021

Multiple Myeloma Trial (Iberdomide, Daratumumab/rHuPH20 Co-formulation)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Oct 25, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 30, 2021

Primary Immunodeficiency Diseases (PID) Trial in United States (SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC,

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)
  • +2 more
  • Cypress, California
  • +10 more
Apr 30, 2021

HIV Antibodies Trial run by the NIAID (VRC-HIVMAB091-00-AB, EDP)

Completed
  • HIV Antibodies
  • VRC-HIVMAB091-00-AB
  • EDP
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 8, 2022

Primary Immunodeficiency Diseases (PID) Trial in Canada, United States (Recombinant human hyaluronidase (rHuPH20)+ immune

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
  • Cypress, California
  • +13 more
Apr 30, 2021

Melanoma, Urothelial Carcinoma Trial in Berlin (Nivolumab/rHuPH20, Nivolumab)

Not yet recruiting
  • Melanoma
  • Urothelial Carcinoma
  • Berlin, Germany
    Local Institution - 0001
Aug 9, 2022

Tumors by Site Trial in Worldwide (nivolumab, rHuPH20)

Active, not recruiting
  • Neoplasms by Site
  • nivolumab
  • rHuPH20
  • Atlanta, Georgia
  • +35 more
Jan 6, 2023

Hereditary Angioedema Trial in United States (CINRYZE with rHuPH20)

Completed
Has Results
  • Hereditary Angioedema
  • CINRYZE with rHuPH20
  • Scottsdale, Arizona
  • +3 more
Jun 16, 2021

Melanoma Trial in Worldwide (relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab)

Not yet recruiting
  • Melanoma
  • Anchorage, Alaska
  • +28 more
Oct 20, 2023

Melanoma Trial in Fort Wayne, Barcelona (Nivolumab/rHuPH20, Nivolumab)

Recruiting
  • Melanoma
  • Nivolumab/rHuPH20
  • Nivolumab
  • Fort Wayne, Indiana
  • +1 more
May 10, 2022

Primary Immunodeficiency Diseases (PID) Trial in United States (Immune Globulin Infusion (Human), 10%, Recombinant human

Completed
Has Results
  • Primary Immunodeficiency Diseases (PID)
  • Immune Globulin Infusion (Human), 10%
  • Recombinant human hyaluronidase
  • Irvine, California
  • +9 more
Apr 30, 2021

HIV Trial in Puerto Rico, United States (VH3810109, Cabotegravir, Standard of care (SOC))

Not yet recruiting
  • HIV Infections
  • VH3810109
  • +3 more
  • Birmingham, Alabama
  • +42 more
Aug 9, 2023